vaxsafe ms vaccine (living)
bioproperties pty. ltd. - mycoplasma synoviae strain ms-h vaccine, living - misc. aural, ophthalmic, oro/naso pharyngeal - mycoplasma synoviae strain ms-h vaccine, living vaccine-general active 105.7 ccu/dose - immunotherapy - poultry broilers (meat for human consum) | poultry layers (eggs for human consump) | poultry pullets (growing chook) | breeding - airsacculitis | chronic respiratory disease | infectious synovitis | vaccine | equine rotavirus | ms
vaxsafe mg vaccine (living)
bioproperties pty. ltd. - mycoplasma gallisepticum strain ts-11 - misc. vaccines or anti sera - mycoplasma gallisepticum strain ts-11 vaccine-general active 0.0 ccu/dose - immunotherapy - poultry layers (eggs for human consump) | caged layers | chickens | chooks | hen - chronic respiratory disease | mycoplasma gallisepticum | vaccine | chronic respiratory disease (c | equine rotavirus | infectious sinusitis
acam2000 smallpox vaccine (live vaccinia virus) vial with diluent
emergent sales and marketing australia pty ltd - vaccinia virus, quantity: 100000000 pfu/ml - injection, powder for - excipient ingredients: sodium chloride; albumin; neomycin sulfate; mannitol; hepes; polymyxin b sulfate - acam2000 is indicated for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection in an officially declared outbreak.
prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics
novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1) - influenza, human, immunization, disease outbreaks - vaccines, - active immunisation against h5n1 subtype of influenza a virus., this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain., prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.,
vaxsafe nd vaccine (living)
bioproperties pty. ltd. - newcastle disease strain v-4 virus - misc. vaccines or anti sera - newcastle disease strain v-4 virus vaccine-viral active 0.0 eid 50/d - immunotherapy - poultry broilers (meat for human consum) | chickens | chooks | meat birds - newcastle disease
prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics
novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1) - influenza, human - vaccines - active immunisation against h5n1 subtype of influenza a virus.; this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain.; prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.
pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)
astrazeneca ab - reassortant influenza virus (live attenuated) of the following strain: a/vietnam/1203/2004 (h5n1) strain - influenza, human - vaccines - prophylaxis of influenza in an officially declared pandemic situation in children and adolescents from 12 months to less than 18 years of age.pandemic influenza vaccine h5n1 astrazeneca should be used in accordance with official guidance
vaxsafe ris vaccine (living)
bioproperties pty. ltd. - marek's disease - misc. vaccines or anti sera - marek's disease vaccine-general active 0.0 p - immunotherapy - poultry | breeders | broiler | chickens | chicks | chooks | day old chicks | hatchlings | layers - vaccine | equine rotavirus
protech bb bordetella bronchiseptica killed vaccine
boehringer ingelheim animal health australia pty. ltd. - bordetella bronchiseptica killed vaccine - misc. vaccines or anti sera - bordetella bronchiseptica killed vaccine vaccine-microbial active 0.0 p - immunotherapy - dog | bitch | castrate | puppy - bordetella bronchiseptica | canine cough syndrome | infectious tracheobronchitis
acam2000 (smallpox- vaccinia vaccine, live injection, powder, lyophilized, for solution
emergent product development gaithersburg inc. - vaccinia virus strain new york city board of health live antigen (unii: 4sv59689sk) (vaccinia virus strain new york city board of health live antigen - unii:4sv59689sk) - acam2000® is indicated for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection. there are very few absolute contraindications to this vaccine for those who are at high risk for smallpox. the risk for experiencing serious vaccination complications must be weighed against the risks for experiencing a potentially fatal smallpox infection. see warnings and precautions (5) for persons who are at higher risk of experiencing serious vaccination complications. severe immune deficiency severe localized or systemic infection with vaccinia (progressive vaccinia) may occur in persons with weakened immune systems. individuals with severe immunodeficiency who are not expected to benefit from the vaccine should not receive acam2000. these individuals may include individuals who are undergoing bone marrow transplantation or individuals with primary or acquired immunodeficiency who require isolation. acam2000 has not been studied in pregnant women. live vaccini